291 related articles for article (PubMed ID: 30979533)
1. Combination versus mono-therapy as salvage treatment for advanced biliary tract cancer: A comprehensive meta-analysis of published data.
Ying J; Chen J
Crit Rev Oncol Hematol; 2019 Jul; 139():134-142. PubMed ID: 30979533
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy and targeted therapy for advanced biliary tract cancers: an umbrella review.
Wang Y; Wen N; Wang S; Nie G; Tian Y; Lu J; Li B
BMC Cancer; 2023 Apr; 23(1):378. PubMed ID: 37098481
[TBL] [Abstract][Full Text] [Related]
3. Comparison of FOLFIRINOX Chemotherapy with Other Regimens in Patients with Biliary Tract Cancers: a Retrospective Study.
Kus T; Aktas G; Kalender ME; Sevinc A; Camci C
J Gastrointest Cancer; 2017 Jun; 48(2):170-175. PubMed ID: 27714651
[TBL] [Abstract][Full Text] [Related]
4. Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues.
Brieau B; Dahan L; De Rycke Y; Boussaha T; Vasseur P; Tougeron D; Lecomte T; Coriat R; Bachet JB; Claudez P; Zaanan A; Soibinet P; Desrame J; Thirot-Bidault A; Trouilloud I; Mary F; Marthey L; Taieb J; Cacheux W; Lièvre A
Cancer; 2015 Sep; 121(18):3290-7. PubMed ID: 26052689
[TBL] [Abstract][Full Text] [Related]
5. Second-line chemotherapy in advanced biliary cancer: a systematic review.
Lamarca A; Hubner RA; David Ryder W; Valle JW
Ann Oncol; 2014 Dec; 25(12):2328-2338. PubMed ID: 24769639
[TBL] [Abstract][Full Text] [Related]
6. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis.
Raggi D; Miceli R; Sonpavde G; Giannatempo P; Mariani L; Galsky MD; Bellmunt J; Necchi A
Ann Oncol; 2016 Jan; 27(1):49-61. PubMed ID: 26487582
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients.
Kim BJ; Yoo C; Kim KP; Hyung J; Park SJ; Ryoo BY; Chang HM
Br J Cancer; 2017 Feb; 116(5):561-567. PubMed ID: 28081540
[TBL] [Abstract][Full Text] [Related]
8. Correlation between efficacy endpoints in patients with advanced biliary tract cancer treated by systemic second-line therapies: Analysis of aggregated data from a systematic literature review.
Neuzillet C; Malka D; Lièvre A; Khurana IS; Vernerey D
Clin Res Hepatol Gastroenterol; 2022 Dec; 46(10):102010. PubMed ID: 35988887
[TBL] [Abstract][Full Text] [Related]
9. An Assessment of Combination of the Camrelizumab With Chemotherapy in Metastatic Biliary Tract Cancers.
Yu Y; Huang S; Chen J; Yu F; Zhang L; Xiang X; Deng J; Fang Z; Li J; Xiong J
Cancer Control; 2021; 28():10732748211017165. PubMed ID: 33982628
[TBL] [Abstract][Full Text] [Related]
10. Comparison between Fluoropyrimidine-Cisplatin and Gemcitabine-Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Meta-Analysis.
Zheng T; Jin J; Zhou L; Zhang Y
Oncol Res Treat; 2020; 43(9):460-469. PubMed ID: 32629449
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy.
Ueno M; Morizane C; Furukawa M; Sakai D; Komatsu Y; Nakai Y; Tsuda M; Ozaka M; Mizuno N; Muto M; Fukutomi A; Ikeda M; Tsuji A; Katanuma A; Moriwaki T; Kajiwara T; Ishii H; Negoro Y; Shimizu S; Nemoto N; Kobayashi S; Makino K; Furuse J
Cancer Med; 2021 Mar; 10(6):2088-2099. PubMed ID: 33635605
[TBL] [Abstract][Full Text] [Related]
12. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.
Skoetz N; Will A; Monsef I; Brillant C; Engert A; von Tresckow B
Cochrane Database Syst Rev; 2017 May; 5(5):CD007941. PubMed ID: 28541603
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of Efficacy and Safety of Different Therapeutic Regimens as
Second-line Treatment for Small Cell Lung Cancer].
Li Z; Liu X; Li J; Gao H; Tang C; Li X; Guo W; Qin H; Wang W; Qu L; Chen J
Zhongguo Fei Ai Za Zhi; 2015 May; 18(5):280-8. PubMed ID: 25975298
[TBL] [Abstract][Full Text] [Related]
14. Fluoropyrimidine-based doublet chemotherapy as second-line treatment for advanced biliary tract cancer: a meta-analysis of ABC-06 and NIFTY.
Rizzo A; Cusmai A; Giovannelli F; Acquafredda S; Rinaldi L; Misino A; Palmiotti G
Expert Rev Gastroenterol Hepatol; 2022 Mar; 16(3):273-278. PubMed ID: 35220866
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes of immune checkpoint inhibitor combined with other targeted or immunological therapy regimens for the treatment of advanced bile tract cancer: a systematic review and meta-analysis.
Zhou J; Li J; Fan Z; Lv G; Wang G
Front Immunol; 2024; 15():1378760. PubMed ID: 38840927
[TBL] [Abstract][Full Text] [Related]
16. Comparison of single agent versus combined chemotherapy in previously treated patients with advanced urothelial carcinoma: a meta-analysis.
Wu XJ; Zhi Y; He P; Zhou XZ; Zheng J; Chen ZW; Zhou ZS
Onco Targets Ther; 2016; 9():1535-43. PubMed ID: 27042121
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy for advanced gallbladder cancer (GBC): A systematic review and meta-analysis.
Azizi AA; Lamarca A; McNamara MG; Valle JW
Crit Rev Oncol Hematol; 2021 Jul; 163():103328. PubMed ID: 33862244
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of anlotinib plus anti-PD-1 agents in patients with refractory advanced biliary tract cancers.
An T; Hui Q; Zong H; Liu L; Cao X; Li R; Hu S; Liu Y; Li J; Zhao R
Clin Transl Oncol; 2024 Mar; ():. PubMed ID: 38530557
[TBL] [Abstract][Full Text] [Related]
19. Continuation of trastuzumab beyond progression in HER2-positive advanced esophagogastric cancer: a meta-analysis.
Ter Veer E; van den Ende T; Creemers A; de Waal L; van Oijen MGH; van Laarhoven HWM
Acta Oncol; 2018 Dec; 57(12):1599-1604. PubMed ID: 30264641
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of gemcitabine-based chemotherapies in biliary tract cancer: a meta-analysis.
Liu H; Zhang QD; Li ZH; Zhang QQ; Lu LG
World J Gastroenterol; 2014 Dec; 20(47):18001-12. PubMed ID: 25548500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
